vs
Consensus Cloud Solutions, Inc.（CCSI）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是Consensus Cloud Solutions, Inc.的1.5倍（$127.1M vs $87.1M），再鼎医药同比增速更快（17.1% vs 0.1%），Consensus Cloud Solutions, Inc.自由现金流更多（$7.3M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs -0.6%）
Consensus Cloud Solutions是一家云解决方案提供商，核心产品包括加密数字传真、安全文档交换、工作流程自动化工具，主要面向医疗、法律、金融服务等领域的北美企业客户提供相关服务。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
CCSI vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.5倍
$87.1M
营收增速更快
ZLAB
高出17.0%
0.1%
自由现金流更多
CCSI
多$34.0M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
-0.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $87.1M | $127.1M |
| 净利润 | $20.5M | — |
| 毛利率 | 80.0% | 51.0% |
| 营业利润率 | 41.1% | -54.6% |
| 净利率 | 23.5% | — |
| 营收同比 | 0.1% | 17.1% |
| 净利润同比 | 13.5% | — |
| 每股收益（稀释后） | $1.06 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCSIZLAB
| Q4 25 | $87.1M | $127.1M | ||
| Q3 25 | $87.8M | $115.4M | ||
| Q2 25 | $87.7M | $109.1M | ||
| Q1 25 | $87.1M | $105.7M | ||
| Q4 24 | $87.0M | $108.5M | ||
| Q3 24 | $87.8M | $101.8M | ||
| Q2 24 | $87.5M | $100.1M | ||
| Q1 24 | $88.1M | $87.1M |
净利润CCSIZLAB
| Q4 25 | $20.5M | — | ||
| Q3 25 | $22.1M | $-36.0M | ||
| Q2 25 | $20.8M | $-40.7M | ||
| Q1 25 | $21.2M | $-48.4M | ||
| Q4 24 | $18.1M | — | ||
| Q3 24 | $21.1M | $-41.7M | ||
| Q2 24 | $23.9M | $-80.3M | ||
| Q1 24 | $26.4M | $-53.5M |
毛利率CCSIZLAB
| Q4 25 | 80.0% | 51.0% | ||
| Q3 25 | 80.0% | 59.5% | ||
| Q2 25 | 79.9% | 60.6% | ||
| Q1 25 | 79.3% | 63.6% | ||
| Q4 24 | 79.5% | 61.5% | ||
| Q3 24 | 79.9% | 64.1% | ||
| Q2 24 | 80.4% | 64.9% | ||
| Q1 24 | 80.7% | 61.4% |
营业利润率CCSIZLAB
| Q4 25 | 41.1% | -54.6% | ||
| Q3 25 | 43.2% | -42.3% | ||
| Q2 25 | 44.5% | -50.3% | ||
| Q1 25 | 43.0% | -53.3% | ||
| Q4 24 | 38.4% | -62.6% | ||
| Q3 24 | 43.8% | -66.6% | ||
| Q2 24 | 45.6% | -76.0% | ||
| Q1 24 | 42.7% | -80.7% |
净利率CCSIZLAB
| Q4 25 | 23.5% | — | ||
| Q3 25 | 25.2% | -31.2% | ||
| Q2 25 | 23.7% | -37.3% | ||
| Q1 25 | 24.3% | -45.8% | ||
| Q4 24 | 20.8% | — | ||
| Q3 24 | 24.1% | -40.9% | ||
| Q2 24 | 27.3% | -80.2% | ||
| Q1 24 | 29.9% | -61.4% |
每股收益（稀释后）CCSIZLAB
| Q4 25 | $1.06 | $-0.05 | ||
| Q3 25 | $1.15 | $-0.03 | ||
| Q2 25 | $1.07 | $-0.04 | ||
| Q1 25 | $1.07 | $-0.04 | ||
| Q4 24 | $0.92 | $-0.09 | ||
| Q3 24 | $1.09 | $-0.04 | ||
| Q2 24 | $1.24 | $-0.08 | ||
| Q1 24 | $1.37 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $74.7M | $689.6M |
| 总债务越低越好 | $558.4M | — |
| 股东权益账面价值 | $13.8M | $715.5M |
| 总资产 | $663.8M | $1.2B |
| 负债/权益比越低杠杆越低 | 40.54× | — |
8季度趋势，按日历期对齐
现金及短期投资CCSIZLAB
| Q4 25 | $74.7M | $689.6M | ||
| Q3 25 | $97.6M | $717.2M | ||
| Q2 25 | $57.9M | $732.2M | ||
| Q1 25 | $53.4M | $757.3M | ||
| Q4 24 | $33.5M | $779.7M | ||
| Q3 24 | $54.6M | $616.1M | ||
| Q2 24 | $49.2M | $630.0M | ||
| Q1 24 | $61.5M | $650.8M |
总债务CCSIZLAB
| Q4 25 | $558.4M | — | ||
| Q3 25 | $578.6M | — | ||
| Q2 25 | $578.2M | — | ||
| Q1 25 | $583.7M | — | ||
| Q4 24 | $593.0M | — | ||
| Q3 24 | $612.5M | — | ||
| Q2 24 | $642.8M | — | ||
| Q1 24 | $671.7M | — |
股东权益CCSIZLAB
| Q4 25 | $13.8M | $715.5M | ||
| Q3 25 | $-2.6M | $759.9M | ||
| Q2 25 | $-26.5M | $791.7M | ||
| Q1 25 | $-49.4M | $810.8M | ||
| Q4 24 | $-79.5M | $840.9M | ||
| Q3 24 | $-93.2M | $667.7M | ||
| Q2 24 | $-124.4M | $704.2M | ||
| Q1 24 | $-151.8M | $762.2M |
总资产CCSIZLAB
| Q4 25 | $663.8M | $1.2B | ||
| Q3 25 | $675.0M | $1.2B | ||
| Q2 25 | $641.5M | $1.2B | ||
| Q1 25 | $629.6M | $1.2B | ||
| Q4 24 | $602.2M | $1.2B | ||
| Q3 24 | $622.5M | $985.3M | ||
| Q2 24 | $608.5M | $987.4M | ||
| Q1 24 | $620.8M | $988.4M |
负债/权益比CCSIZLAB
| Q4 25 | 40.54× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $15.2M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $7.3M | $-26.7M |
| 自由现金流率自由现金流/营收 | 8.4% | -21.0% |
| 资本支出强度资本支出/营收 | 9.1% | 0.5% |
| 现金转化率经营现金流/净利润 | 0.74× | — |
| 过去12个月自由现金流最近4个季度 | $105.9M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流CCSIZLAB
| Q4 25 | $15.2M | $-26.0M | ||
| Q3 25 | $51.6M | $-32.0M | ||
| Q2 25 | $28.3M | $-31.0M | ||
| Q1 25 | $40.9M | $-61.7M | ||
| Q4 24 | $11.1M | $-55.8M | ||
| Q3 24 | $41.6M | $-26.8M | ||
| Q2 24 | $24.4M | $-42.2M | ||
| Q1 24 | $44.7M | $-90.1M |
自由现金流CCSIZLAB
| Q4 25 | $7.3M | $-26.7M | ||
| Q3 25 | $44.4M | $-35.0M | ||
| Q2 25 | $20.3M | $-33.9M | ||
| Q1 25 | $33.7M | $-63.2M | ||
| Q4 24 | $3.1M | $-58.4M | ||
| Q3 24 | $33.6M | $-28.2M | ||
| Q2 24 | $15.8M | $-42.9M | ||
| Q1 24 | $35.8M | $-91.1M |
自由现金流率CCSIZLAB
| Q4 25 | 8.4% | -21.0% | ||
| Q3 25 | 50.6% | -30.4% | ||
| Q2 25 | 23.2% | -31.1% | ||
| Q1 25 | 38.7% | -59.9% | ||
| Q4 24 | 3.6% | -53.8% | ||
| Q3 24 | 38.3% | -27.7% | ||
| Q2 24 | 18.1% | -42.9% | ||
| Q1 24 | 40.6% | -104.5% |
资本支出强度CCSIZLAB
| Q4 25 | 9.1% | 0.5% | ||
| Q3 25 | 8.2% | 2.6% | ||
| Q2 25 | 9.1% | 2.6% | ||
| Q1 25 | 8.3% | 1.5% | ||
| Q4 24 | 9.2% | 2.4% | ||
| Q3 24 | 9.1% | 1.3% | ||
| Q2 24 | 9.8% | 0.7% | ||
| Q1 24 | 10.1% | 1.1% |
现金转化率CCSIZLAB
| Q4 25 | 0.74× | — | ||
| Q3 25 | 2.34× | — | ||
| Q2 25 | 1.36× | — | ||
| Q1 25 | 1.94× | — | ||
| Q4 24 | 0.62× | — | ||
| Q3 24 | 1.97× | — | ||
| Q2 24 | 1.02× | — | ||
| Q1 24 | 1.69× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CCSI
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
